A recent study showed that ST6GAL1 overexpression induces α-2,6-sialylation of FGFR1 and that high levels of ST6GAL1 decrease the anticancer effect of the FGFR1 inhibitor PD173047 in ovarian cancer cells [69]. Here, ST6GAL1 is linked to ovarian carcinoma.